Navigation Links
MS drug shows promise for preventing heart failure
Date:7/16/2013

A drug already approved to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy, or thickening of the cardiac muscle--a disorder that often leads to heart failure, researchers at the University of Illinois at Chicago College of Medicine report.

The findings are published in the July 16 issue of Circulation: Heart Failure.

Cardiac hypertrophy is a slow thickening of the heart muscle that shrinks the interior volume of the heart, forcing the organ to work harder to pump a diminishing volume of blood.

"There comes a day when the heart just can't keep up any more, and it fails," says R. John Solaro, UIC distinguished university professor and head of physiology and biophysics.

Cardiac hypertrophy, which afflicts one in 500 people, can be caused by high blood pressure or inherited through genes that control contraction of the heart.

Solaro and his colleagues believe that if the thickening of the heart muscle could be slowed, or maybe even reversed, heart failure could be prevented.

Solaro and his UIC colleague Yunbo Ke, research assistant professor of physiology and biophysics, were interested in a chemical derived from a fungus used in traditional Chinese medicine as an eternal-youth nostrum. That compound, designated FTY-720, has been developed into a drug to treat multiple sclerosis and is a chemical cousin to the drug most widely used to suppress the immune system and prevent organ rejection in transplant patients.

The substance, Solaro said, "mimics certain lipids in the body that play a role in the development of cardiac hypertrophy."

Using an experimental mouse model of cardiac hypertrophy, Solaro and his team found that FTY-720 significantly reduced heart mass; lessened fibrosis, or stiffening of the heart muscle; and improved overall cardiac function in the mice that received the drug.

The researchers also showed that the drug inhibits expression of several genes involved in cardiac hypertrophy.

"We saw that FTY-720 blocked the activity of a protein we know is involved in causing heart-cell thickening," said Solaro. When that protein is blocked, he said, collagen and other proteins involved in heart-cell thickening are also down-regulated.

Collagen, a fibrous protein found between heart cells, causes the heart muscle to become stiff. Collagen is often overabundant in people with cardiac hypertrophy.

"When the heart muscle is stiff, it actually takes effort to relax the heart and allow blood to flow into the ventricles, so this is another way this disease causes the heart to work harder than it should have to," Solaro said.

"FTY-720 is a potential therapy to treat this disease and prevent heart failure for people where the disease is acquired through high blood pressure, and possibly inherited hypertrophy as well," he said.


'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Related biology news :

1. Genetic survey of endangered Antarctic blue whales shows surprising diversity
2. University of Houston study shows BP oil spill hurt marshes, but recovery possible
3. Weakness can be an advantage in surviving deadly parasites, a new study shows
4. Study shows unified process of evolution in bacteria and sexual eukaryotes
5. Sexual reproduction brings long-term benefits, study shows
6. UCSB study shows forest insects and diseases arrive in US via imported plants
7. Study shows botanical formula fights prostate cancer
8. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
9. Buy coal? New analysis shows purchasing fossil fuel deposits best way to fight climate change
10. Global Surgical Devices Market Growth Driven by Improving Standards of Living and Longer Life Expectancies, Research Shows
11. CU research shows warming climate threatens ecology at mountain research site west of Boulder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
Breaking Biology Technology: